Inventisbio Co., Ltd

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if D-2570 can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for 6 months…

This study compares a new oral drug, D-0502, to a standard injected drug (fulvestrant) in people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 640 participants whose cancer has worsened after prior hormone therapy will be randomly assigned to on…

This study tests a new drug called D-2570 for people with active psoriatic arthritis, a condition causing joint pain and swelling. About 222 adults aged 18-70 will receive either the drug or a placebo to see if it reduces tender and swollen joints after 12 weeks. The goal is to f…

This study tests whether a new drug, D-2570, can help control active systemic lupus erythematosus (SLE), an autoimmune disease. About 120 adults with moderate-to-severe lupus will receive either D-2570 or a placebo for 48 weeks. The main goal is to see if D-2570 reduces lupus sym…

This study tests an experimental drug called D-2570 in people with moderate to severe plaque psoriasis. About 477 adults will receive either D-2570, a placebo, or an active comparator drug. The goal is to see if D-2570 safely reduces skin symptoms and improves quality of life.